Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company Gross Profit Margin: 75.19%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMY Gross Profit Margin Rankings
| Overall | 81st percentile | 713 of 3939 |
| Sector | 77th percentile | 84 of 374 in Healthcare |
| Industry | 76th percentile | 4 of 17 in Drug Manufacturers - Major |
BMY Gross Profit Margin Range, Past 5 Years
| Minimum | 67.88% | Sep 2007 |
| Maximum | 81.33% | Dec 2008 |
| Average | 72.18% |
About Gross Profit Margin
Gross profit margin is the difference between sales and the cost of goods sold divided by revenue. It expresses the relationship between gross profit (sales - cost of goods sold) and sales revenue. More specifically, gross profit margin represents the percentage of each dollar of a company's revenue that is available to cover fixed costs after paying for the goods or services that were sold.
If a company produces widgets and earns $32 million in sales but pays $24 million for the items sold, then the company's gross profit margin would be ($32m - $24m)/$32m = %25.
Learn More
You may also be interested in these BMY related companies
BMY News
RT @ianestepan $CLDX if this data was from $BMY,$ONXX,$MDVN,$DNA or $PFE - people would be soooooo excited....
about a day ago by N0M0NEY_N0H0NEY
about a day ago by N0M0NEY_N0H0NEY
News related to $BMY, currently +0.5% since open: 'Bristol-Myers says FDA clears Mass. plant' http://stks.co/3q1B
about 10 days ago by TradeBot
about 10 days ago by TradeBot
Six Suitors Join $BMY in Considering a Bid for $AMLN http://stks.co/3psG
about 10 days ago by abubnic
about 10 days ago by abubnic
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 10 days ago by abubnic
about 10 days ago by abubnic
Bristol-Myers (BMY) Announces FDA Approval of Devens, MA Plant for Manufacture of ORENCIA
May 15, 11:17AM Street Insider
May 15, 11:17AM Street Insider
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility
May 15, 11:01AM Benzinga
May 15, 11:01AM Benzinga
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept)
May 15, 11:00AM Business Wire
May 15, 11:00AM Business Wire
NR7 (EOD): Potential bullish NR7. Entry: 33.31. First Target: 34.00. $BMY http://chart.ly/qwxxeih
about 12 days ago by jackdamn
about 12 days ago by jackdamn
$BMY Ipilimumab,also known as MDX-010 or MDX-101 $DNDN Provenge along with $ARNA and $VVUS have been and are my Phamas for the next yr
about 14 days ago by selectstock
about 14 days ago by selectstock
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference
May 10, 11:00AM Business Wire
May 10, 11:00AM Business Wire
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 17 days ago by abubnic
about 17 days ago by abubnic
Listen to $BMY Bristol-Myers Squibb at Deutsche Bank AG Health Care Conference - live at 10:40 AM, ondemand after - http://stks.co/3hTs
about 18 days ago by earningscast
about 18 days ago by earningscast
@russwm thanks working hard here. above 34 is a desc trend break + above 10day. needs to hold 50day $BMY http://chart.ly/mghypbo
about 23 days ago by TraderNewburgh
about 23 days ago by TraderNewburgh
@TraderNewburgh I would love to hear your thoughts on $BMY in the short/medium term, if you have the time. Love your videos.
about 23 days ago by russwm
about 23 days ago by russwm
Listen to $BMY Bristol-Myers Squibb Annual Meeting of Stockholders - live at 10:00 AM, ondemand after - http://stks.co/3bIu
about 24 days ago by earningscast
about 24 days ago by earningscast
http://stks.co/3XIO Health Care Report Take A Look $FURX $BMY $AMLN
about 29 days ago by Stockmarketman2
about 29 days ago by Stockmarketman2
Listen to $BMY Q1 2012 earnings call - live at 10:30 AM, ondemand after - http://stks.co/3WpX
about 29 days ago by earningscast
about 29 days ago by earningscast
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMY | 32.99 | +0.47 | +1.45% | 54.88B |
| BMTI | 2.41 | +0.10 | +4.33% | 64.98M |
| BMRN | 38.51 | +0.47 | +1.24% | 4.398B |
| BMR | 18.42 | +0.05 | +0.27% | 2.833B |
| BLTI | 2.37 | +0.01 | +0.42% | 72.43M |
| BLL | 39.86 | +0.33 | +0.83% | 6.180B |
| BKSC | 11.37 | -0.63 | -5.25% | 50.60M |
| BKR | 22.62 | +0.09 | +0.40% | 214.94M |
| BKMU | 3.52 | +0.03 | +0.86% | 161.69M |
| BKK | 16.22 | +0.12 | +0.75% |